Searching for an effective, safe and universal anti-HIV vaccine: Finding the answer in just one short peptide

Self/Nonself - Immune Recognition and Signaling

Volumn 2, Issue 1, 2011, Pages 49-54

  Lucchese, Guglielmo ^a   Stufano, Angela ^a   Kanduc, Darja ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Conserved viral pentapeptides; HIV versus human peptide overlap; Peptide based anti hiv vaccine; Unique viral pentapeptides; Universal anti hiv vaccine

Indexed keywords

GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PENTAPEPTIDE;

AMINO ACID SEQUENCE; ANTIGEN RECOGNITION; ARTICLE; CROSS REACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; T CELL DEPLETION;

EID: 79960380774     PISSN: 19382030     EISSN: 19382049     Source Type: Journal    
DOI: 10.4161/self.2.1.14762     Document Type: Article

References (46)

1. Boasso A, Shearer GM, Clerici M. The hunt for an HIV vaccine: Time to rethink recent failures. Lancet 2008; 371:1897-8.
2. Ledford H. HIV vaccine developers battle on, despite high-profile failures. Nat Biotechnol 2008; 26:591-2.
3. Bradac J, Dieffenbach CW. HIV vaccine development: Lessons from the past, informing the future. IDrugs 2009; 12:435-9.
4. Thomas C. Roadblocks in HIV research: Five questions. Nat Med 2009; 15:855-9.
5. Wijesundara DK, Jackson RJ, Ramshaw IA, Ranasinghe C. Human immunodeficiency virus-1 vaccine design: where do we go now? Immunol Cell Biol 2010; 89:367-374. doi:10.1038/icb.2010.118.
6. Stingl G. Anti-retroviral therapy in HIV-1-infected persons: Concepts and strategies. Curr Probl Dermatol 1989; 18:250-68.
7. Trabaud MA, Cotte L, Labernardière JL, Lebel-Binay S, Icard V, Tardy JC, et al. Variants with different mutation patterns persist in the quasispecies of enfuvirtide-resistant HIV-1 population during and after treatment in vivo. J Acquir Immune Defic Syndr 2007; 46:134-44.
8. Haynes BF, Fleming J, St. Clair EW, Katinger H, Stiegler G, Kunert R, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005; 308:1906-8.
9. Kanduc D, Stufano A, Lucchese G, Kusalik A. Massive peptide sharing between viral and human proteomes. Peptides 2008; 29:1755-66.
10. Kanduc D. Pentapeptide overlapping between human immunodeficiency viruses and Homo sapiens proteomes is higher than 90%. Retrovirology 2009; 6:44.
11. Lucchese G, Stufano A, Calabro' M, Kanduc D. Charting the peptide crossreactome between HIV-1 and the human proteome. Front Biosci 2011; E3: 1385-1400.
12. Crise B, Buonocore L, Rose JK. CD4 is retained in the endoplasmic reticulum by the human immunodeficiency virus type 1 glycoprotein precursor. J Virol 1990; 64:5585-93.
13. Alfsen A, Iniguez P, Bouguyon E, Bomsel M. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J Immunol 2001; 166:6257-65.
14. Vanden Haesevelde M, Decourt JL, De Leys RJ, Vanderborght B, van der Groen G, van Heuverswijn H, et al. Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate. J Virol 1994; 68:1586-96.
15. Montavon C, Vergne L, Bourgeois A, Mpoudi-Ngole E, Malonga-Mouellet G, Butel C, et al. Identification of a new circulating recombinant form of HIV type 1, CRF11-cpx, involving subtypes A, G, J and CRF01-AE, in Central Africa. AIDS Res Hum Retroviruses 2002; 18:231-6.
16. Vergne L, Bourgeois A, Mpoudi-Ngole E, Mougnutou R, Mbuagbaw J, Liegeois F, et al. Biological and genetic characteristics of HIV infections in Cameroon reveals dual group M and O infections and a correlation between SI-inducing phenotype of the predominant CRF02_AG variant and disease stage. Virology 2003; 310:254-66.
17. Olivares I, Casado Herrero C, Iglesias-Ussel MD, Dietrich U, Lopez Galindez C. Complete sequence of an infectious molecular clone derived from a Spanish HIV type I isolate. AIDS Res Hum Retroviruses 1998; 14:1649-51.
18. Lucchese G, Stufano A, Trost B, Kusalik A, Kanduc D. Peptidology: short amino acid modules in cell biology and immunology. Amino Acids 2007; 33:703-7.
19. Landsteiner K, van der Scheer J. On the serological specificity of peptides. III. J Exp Med 1939; 69:705-19.
20. Smith SC, McAdam WJ, Kemp BE, Morgan FJ, Cotton RG. A monoclonal antibody to the phosphorylated form of phenylalanine hydroxylase: Definition of the phosphopeptide epitope. Biochem J 1987; 244:625-31.
21. Woods JP, Spinola SM, Strobel SM, Cannon JG. Conserved lipoprotein H.8 of pathogenic Neisseria consists entirely of pentapeptide repeats. Mol Microbiol 1989; 3:43-8.
22. Reddehase MJ, Rothbard JB, Koszinowski UH. A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes. Nature 1989; 337:651-3.
23. Okada Y, Nakayama S, Iguchi S, Kikuchi Y, Irie M, Sawada J, et al. Amino acids and peptides. XXXIII. Synthesis of N-terminal epitope peptides of mammalian metallothioneins (MTs). Chem Pharm Bull 1992; 40:1029-32.
24. Sheets RL, Pandey R, Klement V, Grant CK, Roy-Burman P. Biologically selected recombinants between feline leukemia virus (FeLV) subgroup A and an endogenous FeLV element. Virology 1992; 190:849-55.
25. Papadouli I, Sakarellos C, Tzartos SJ. High-resolution epitope mapping and fine antigenic characterization of the main immunogenic region of the acetylcholine receptor: Improving the binding activity of synthetic analogues of the region. Eur J Biochem 1993; 211:227-34.
26. Endo M, Nunomura W, Takakuwa Y, Hatakeyama M, Higashi T. A novel epitope (pentapeptide) in the human hemoglobin beta chain. Hemoglobin 1998; 22:321-31.
27. Tiwari R, Geliebter J, Lucchese A, Mittelman A, Kanduc D. Computational peptide dissection of Melan-a/MART-1 oncoprotein antigenicity. Peptides 2004; 25:1865-71.
28. Kanduc D, Lucchese A, Mittelman A. Non-redundant peptidomes from DAPs: Towards "the vaccine"? Autoimmun Rev 2007; 6:290-4.
29. Stufano A, Capone G, Pesetti B, Polimeno L, Kanduc D. Clustering of rare peptide segments in the HCV immunome. Self/Nonself 2010; 1:154-62.
30. Stufano A, Kanduc D. Proteome-based epitopic peptide scanning along PSA. Exp Mol Pathol 2009; 86:36-40.
31. Lucchese G, Stufano A, Kanduc D. Proposing lowsimilarity peptide vaccines against Mycobacterium tuberculosis. J Biomed Biotechnol 2010; 832-341.
32. Kanduc D. Immunogenicity in peptide-immunotherapy: From self/nonself to similar/dissimilar sequences. Adv Exp Med Biol 2008; 640:198-207.
33. Kanduc D. Correlating low-similarity peptide sequences and allergenic epitopes. Curr Pharm Des 2008; 14:289-95.
34. Kanduc D. Epitopic peptides with low similarity to the host proteome: Towards biological therapies without side effects. Expert Opin Biol Ther 2009; 9:45-53.
35. Kanduc D. ''Self-nonself" peptides in the design of vaccines. Curr Pharm Des 2009; 15:3283-9.
36. Kanduc D. Protein information content resides in rare peptide segments. Peptides 2010; 31:983-8.
37. Kanduc D. The self/nonself issue: A confrontation between proteomes. SelfNonself 2010; 1:255-8.
38. McBurney SP, Ross TM. Viral sequence diversity: challenges for AIDS vaccine designs. Expert Rev Vaccines 2008; 7:1405-17.
39. Nakamura KJ, Gach JS, Jones L, Semrau K, Walter J, Bibollet-Ruche F, et al. 4E10-resistant HIV-1 isolated from four subjects with rare membrane-proximal external region polymorphisms. PLoS One 2010; 5:9786.
40. Adis International Ltd., HIV gp120 vaccine-VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine-Genentech, HIV gp120 vaccine AIDSVAX-VaxGen, HIV vaccine AIDSVAX-VaxGen. Drugs R D 2003; 4:249-53.
41. Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003; 77:6305-13.
42. Gray G, Buchbinder S, Duerr A. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS 2010; 5:357-61.
43. Wilson NA, Watkins DI. Is an HIV vaccine possible? Braz J Infect Dis 2009; 13:304-10.
44. UniProt consortium: The universal protein resource (UniProt) in 2010. Nucleic Acids Res 2010; 38:142-8.
45. Barker WC, Garavelli JS, Huang H, McGarvey PB, Orcutt BC, Srinivasarao GY, et al. The protein information resource (PIR). Nucleic Acids Res 2000; 28:41-4.
46. Poirot O, O'Toole E, Notredame C. Tcoffee@igs: A web server for computing, evaluating and combining multiple sequence alignments. Nucleic Acids Res 2003; 31:3503-6.